{"id":"W2004836183","doi":"10.1158/0008-5472.sabcs10-p3-14-15","title":"Abstract P3-14-15: Lapatinib Plus Capecitabine in Trastuzumab Pre-Treated HER2- Positive Metastatic Breast Cancer: The Canadian Lapatinib Expanded Access Program Experience","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Northeast Cancer Centre; Hôpital Charles-Le Moyne; Regional Municipality of Durham; CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Lapatinib; Medicine; Capecitabine; Trastuzumab; Internal medicine; Metastatic breast cancer; Taxane; Oncology; Breast cancer; Cancer; Progressive disease; Gastroenterology; Tyrosine-kinase inhibitor; Chemotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008996317,0.0004926821,0.000721668,0.0005748821,0.0006599867,0.0003101157,0.001029469,0.0002101172,0.003268576],"category_scores_gemma":[0.0002159965,0.0003603179,0.0001288959,0.002002373,0.001288437,0.0005871975,0.0001646127,0.002416037,0.00002867587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002814785,"about_ca_system_score_gemma":0.005179894,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.6377947,"about_ca_topic_score_gemma":0.8835739,"domain_scores_codex":[0.9948443,0.0002611054,0.0006358687,0.0009748804,0.001464889,0.001818948],"domain_scores_gemma":[0.9963909,0.0003814927,0.0001812722,0.0009495547,0.001246742,0.0008500118],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0074676,0.001315604,0.1204425,0.0005584019,0.000645867,0.0009067784,0.03067116,0.0006368785,0.04983987,0.0001694788,0.00114061,0.7862053],"study_design_scores_gemma":[0.007386359,0.0005372255,0.9549773,0.001005452,0.00008167127,0.0002808012,0.003601077,0.0006365892,0.02302182,0.0001761991,0.007571676,0.0007238142],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854515,0.001090018,0.000007663044,0.00666551,0.0003700742,0.004261308,0.0007018936,0.0001340053,0.001318021],"genre_scores_gemma":[0.9886551,0.0002573407,0.0002435369,0.0004181961,0.000466794,0.009045812,0.00009433697,0.0001232646,0.0006956567],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8345348,"threshold_uncertainty_score":0.9998854,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06690299879045916,"score_gpt":0.4538422047316935,"score_spread":0.3869392059412343,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}